palmerolide A: isolated from the antarctic marine tunicate Synoicum adareanum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 17756325 |
| CHEMBL ID | 573783 |
| SCHEMBL ID | 13080869 |
| MeSH ID | M0513181 |
| Synonym |
|---|
| CHEMBL573783 |
| palmerolide a |
| SCHEMBL13080869 |
| [(2r,4e,6e,10s,11s,12e,14s,18e)-11,14-dihydroxy-4-methyl-2-[(2r,3e,5e)-4-methyl-6-(3-methylbut-2-enoylamino)hexa-3,5-dien-2-yl]-20-oxo-1-oxacycloicosa-4,6,12,18-tetraen-10-yl] carbamate |
Palmerolide A (1) is a macrolide isolated from the Antarctic tunicate Synoicum adareanum that is of interest due to its potential as an antimelanoma drug. Palmerolides has potent and selective activity against the melanoma cancer cell line UACC-62.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Palmerolide A (1) is a macrolide isolated from the Antarctic tunicate Synoicum adareanum that is of interest due to its potential as an antimelanoma drug. " | ( Characterization of the microbial community and polyketide biosynthetic potential in the palmerolide-producing tunicate Synoicum adareanum. Baker, BJ; Murray, AE; Riesenfeld, CS, 2008) | 1.79 |
| "Palmerolide A is a recently disclosed marine natural product possessing striking biological properties, including potent and selective activity against the melanoma cancer cell line UACC-62. " | ( Total synthesis of the originally proposed and revised structures of palmerolide A and isomers thereof. Banerji, B; Chen, DY; Guduru, R; Nicolaou, KC; Sun, YP, 2008) | 2.02 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Palmerolide A displays potent and selective cytotoxicity toward melanoma (UACC-66 LC50 = 0.018 muM) and appears to operate via inhibition (IC50 = 2 nM) of V-ATPase." | ( Palmerolide A, a cytotoxic macrolide from the antarctic tunicate Synoicum adareanum. Amsler, CD; Baker, BJ; Diyabalanage, T; McClintock, JB, 2006) | 2.5 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID627744 | Cytotoxicity against human NCI60 cells | 2011 | Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22 | Palmerolide macrolides from the Antarctic tunicate Synoicum adareanum. |
| AID627741 | Inhibition of bovine brain Vo domain of V-ATPase activity assessed as ATP-mediated proton translocation by spectrophotometric analysis | 2011 | Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22 | Palmerolide macrolides from the Antarctic tunicate Synoicum adareanum. |
| AID627743 | Ratio of IC50 for bovine brain Vo domain of V-ATPase activity to IC50 for human UACC62 cells | 2011 | Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22 | Palmerolide macrolides from the Antarctic tunicate Synoicum adareanum. |
| AID436157 | Cytotoxicity against human UACC62 cells | 2008 | Journal of natural products, Nov, Volume: 71, Issue:11 | Characterization of the microbial community and polyketide biosynthetic potential in the palmerolide-producing tunicate Synoicum adareanum. |
| AID627742 | Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay | 2011 | Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22 | Palmerolide macrolides from the Antarctic tunicate Synoicum adareanum. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.97) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (6.25%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (93.75%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||